A director at Global Partners Lp sold 9,000 shares at 51.440USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
First Northwest Bancorp and First Fed Bank name Curt Queyrouze as CEO and President PORT ANGELES, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- First Northwest Bancorp (Nasdaq: FNWB) (“First Northwest”) and its subsidiary First Fed Bank (“First Fed” and, together with First Northwest, the “Company”) are pleased to announce today that Curt Queyrouze will become the Company’s new Chief Executive Officer and President, starting on September 17, 2025. He will also be appointed as a member of the Board of Directors of both First Northwest and First Fed at that time. “It's a privilege ...
First Fed Foundation Invites Final Applications for Fall Grant Cycle PORT ANGELES, Wash., Aug. 25, 2025 (GLOBE NEWSWIRE) -- The First Fed Foundation is pleased to remind nonprofit, tribal, government, and school district organizations serving Clallam, Jefferson, Kitsap, Whatcom Counties, and the city of Bellevue that the Fall 2025 grant application cycle is still open—but not much longer. Applications will be accepted through 11:59 PM on Monday, September 1, 2025. About First Fed FoundationFounded in 2015 with a generous $12 million gift in cash and stock from First Northwest Bancorp (NA...
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditionsAs of June 30, 2025, cash and cash equivalents were $62.3 millionIn light of the pending transaction, Y-mAbs will not be holding a webcast and co...
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will no...
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics Acquisition to Include Naxitamab-gqgk DANYELZA® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product Portfolio Transaction Expands SERB’s Investment in the U.S. SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 Per Share Represents 105% Premium to Y-mAbs Closing Share Price on August 4, 2025 WEST CONSHOHOCKEN, Pa. and PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on medicines for rare d...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.